Stock News

EPS for Tandem Diabetes Care, Inc. (TNDM) Expected At $-1.30; 6 Bullish Analysts Covering Knowles (KN)

Among 13 analysts covering Knowles Corporation (NYSE:KN), 6 have Buy rating, 2 Sell and 5 Hold. Therefore 46% are positive. Knowles Corporation had 24 analyst reports since August 20, 2015 according to SRatingsIntel. The company was maintained on Thursday, February 8 by Craig Hallum. Roth Capital initiated the shares of KN in report on Thursday, September 29 with “Buy” rating. FBR Capital maintained the shares of KN in report on Friday, February 12 with “Underperform” rating. The firm earned “Sell” rating on Thursday, September 17 by Zacks. The firm earned “Negative” rating on Tuesday, September 20 by Susquehanna. The stock has “Hold” rating by Benchmark on Wednesday, June 29. The stock of Knowles Corporation (NYSE:KN) earned “Neutral” rating by JP Morgan on Tuesday, September 6. The company was upgraded on Monday, September 28 by FBR Capital. The stock of Knowles Corporation (NYSE:KN) has “Buy” rating given on Monday, January 4 by Craig Hallum. Susquehanna maintained Knowles Corporation (NYSE:KN) on Thursday, February 8 with “Hold” rating. See Knowles Corporation (NYSE:KN) latest ratings:

08/02/2018 Broker: Susquehanna Rating: Hold New Target: $15.0 Maintain
08/02/2018 Broker: Roth Capital Rating: Buy New Target: $18.0 Maintain
08/02/2018 Broker: Craig Hallum Rating: Buy New Target: $17.0 Maintain
21/12/2017 Broker: PiperJaffray Rating: Neutral New Target: $15.5 Initiates Coverage On
20/12/2017 Broker: Piper Jaffray Rating: Hold New Target: $15.5 Initiate
05/12/2017 Broker: Robert W. Baird Rating: Buy New Target: $18.0 Maintain
25/10/2017 Broker: Susquehanna Rating: Hold New Target: $16.0
13/09/2017 Broker: Roth Capital Rating: Buy New Target: $20.0

Analysts expect Tandem Diabetes Care, Inc. (NASDAQ:TNDM) to report $-1.30 EPS on March, 14.They anticipate $3.50 EPS change or 72.92% from last quarter’s $-4.8 EPS. After having $-3.09 EPS previously, Tandem Diabetes Care, Inc.’s analysts see -57.93% EPS growth. The stock increased 1.24% or $0.03 during the last trading session, reaching $2.44. About 381,655 shares traded. Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has declined 86.78% since February 16, 2017 and is downtrending. It has underperformed by 103.48% the S&P500.

Among 9 analysts covering Tandem Diabetes Care (NASDAQ:TNDM), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. Tandem Diabetes Care had 20 analyst reports since August 5, 2015 according to SRatingsIntel. The firm earned “Underperform” rating on Thursday, March 24 by Bank of America. The stock of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has “Hold” rating given on Thursday, October 5 by Piper Jaffray. As per Monday, August 10, the company rating was maintained by Deutsche Bank. Robert W. Baird downgraded the stock to “Neutral” rating in Wednesday, November 2 report. Feltl & Co downgraded the stock to “Buy” rating in Wednesday, November 2 report. The company was downgraded on Thursday, November 3 by PiperJaffray. The stock has “Hold” rating by Zacks on Saturday, August 22. The stock has “Hold” rating by Zacks on Friday, September 4. The company was maintained on Friday, November 17 by Robert W. Baird. The firm has “Buy” rating by Zacks given on Thursday, August 20.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company has market cap of $97.89 million. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set. It currently has negative earnings. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system.

Investors sentiment increased to 0.59 in Q3 2017. Its up 0.04, from 0.55 in 2017Q2. It increased, as 24 investors sold Tandem Diabetes Care, Inc. shares while 8 reduced holdings. 10 funds opened positions while 9 raised stakes. 7.03 million shares or 59.85% less from 17.51 million shares in 2017Q2 were reported. Stifel Fincl stated it has 0% of its portfolio in Tandem Diabetes Care, Inc. (NASDAQ:TNDM). Virtu Limited Liability holds 99,567 shares or 0% of its portfolio. Raymond James & Associates accumulated 15,000 shares. Keybank Natl Association Oh invested 0% of its portfolio in Tandem Diabetes Care, Inc. (NASDAQ:TNDM). First Mercantile Tru has 58,361 shares for 0.01% of their portfolio. Appleton Partners Ma has 26,700 shares for 0% of their portfolio. Pnc Fincl Group Inc invested in 115 shares or 0% of the stock. 2,589 are held by Meeder Asset Mngmt. Citigroup holds 10,000 shares. Group Inc One Trading Lp accumulated 30,451 shares or 0% of the stock. Vanguard Group Inc Inc accumulated 1.40 million shares. Royal Bank Of Canada, Ontario – Canada-based fund reported 2,816 shares. 500,000 are owned by Adage Capital Prns Gru. Rock Springs Capital Mgmt L P has 562,500 shares for 0.02% of their portfolio. Weiss Multi reported 20,000 shares stake.

The stock increased 0.70% or $0.1 during the last trading session, reaching $14.39. About 257,950 shares traded. Knowles Corporation (NYSE:KN) has risen 40.62% since February 16, 2017 and is uptrending. It has outperformed by 23.92% the S&P500.

Leave a Reply

Your email address will not be published. Required fields are marked *